Stifel raised the firm’s price target on Stericycle to $75 from $70 and keeps a Buy rating on the shares. The company exited FY23 with sufficient operating leverage momentum to support its long-term thesis of 13%-17% EBITDA compound annual growth revenue and focus on its 50%-60% free-cash-flow conversion of EBITDA, the analyst tells investors. Further, topline growth has been hovering around 3%-5% by segment for some time and should settle into a stable trend, the firm adds.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on SRCL:
- Stericycle reports Q4 adjusted EPS 54c, consensus 47c
- Stericycle, Inc. Reports Results For The Fourth Quarter 2023
- SRCL Earnings this Week: How Will it Perform?
- Stericycle to Present at Raymond James 45th Annual Institutional Investors Conference in March
- Stericycle price target raised to $50 from $45 at Truist
